# US 2015/0071876 A1 · Combined measles-malaria vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0071876 A1
- Document ID: US20150071876A1
- Status: Published application
- Kind: A1
- Application number: 14/486,578
- Filed: 2014-09-15
- Published: 2015-03-12
- Earliest claimed: 2009-05-05
- Assignees: Cadila Healthcare Limited
- Applicants: Cadila Healthcare Limited
- Inventors: Reinhard GLUECK; Agata FAZIO; Viviana GIANINO; Martin A. BILLETER
- Web page: https://patentgrep.com/patent/US20150071876A1

## CPC

- A61K 39/165: Mumps or measles virus
- A61K 38/2013: {IL-2}
- A61K 39/0015: {Combination vaccines based on measles-mumps-rubella}
- A61K 39/015: Hemosporidia antigens, e.g. Plasmodium antigens
- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/22: for herpes viruses
- A61P 33/06: Antimalarials
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 35/13: Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00)
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55588: {Adjuvants of undefined constitution}
- A61K 2039/575: {humoral response}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2760/18421: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/18434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18442: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2760/18443: viral genome or elements thereof as genetic vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.

## Claims

### Claim at position 1

1-42. (canceled)

### Claim 43

A combined measles-malaria vaccine comprising a recombinant measles vaccine virus which express malaria antigens capable of eliciting immune response and protection both against measles and CS malaria.

### Claim 44 (depends on 43)

The combined measles-malaria vaccine as claimed in claim 43, wherein the recombinant measles vaccine virus expresses single or different malaria antigens.

### Claim 45 (depends on 43)

The combined measles-malaria vaccine as claimed in claim 43, wherein the recombinant measles vaccine virus expresses CS malaria antigen in both anchored and secreted forms.

### Claim 46 (depends on 43)

The combined measles-malaria vaccine as claimed in claim 43, wherein the recombinant measles vaccine virus expresses CS malaria antigen in both anchored and secreted forms 3D7 strain and MAD 20 preferably the FCB1 strain.

### Claim 47 (depends on 43)

The combined measles-malaria vaccine as claimed in claim 43, wherein the recombinant measles vaccine virus expresses CS malaria antigen in both anchored and secreted forms FCB1 strain.

### Claim 48 (depends on 43)

The combined measles-malaria vaccine as claimed in claim 43, wherein the malaria antigen is cloned between P and M or H and L protein of recombinant measles vaccine virus.

### Claim 49

A measles vaccine virus vector comprising the nucleotide sequence of antigen of malaria.

### Claim 50 (depends on 49)

The vector as claimed in claim 49, wherein the nucleotide sequence is selected from FIG. 26 to FIG. 35.

### Claim 51 (depends on 49)

The vector as claimed in claim 49, wherein the measles vaccine virus vector further comprises nucleotide sequence selected from FIG. 24 to FIG. 25.

### Claim 52 (depends on 49)

A host comprising the vector of claim 49.

### Claim 53 (depends on 49)

The host as claimed in claim 49, is selected from E. coli or mammalian cell line.

### Claim 54 (depends on 43)

The combined measles-malaria vaccine as claimed in claim 43, wherein the recombinant measles virus originating from a vaccine strain derived from Edmoston Zagreb.

### Claim 55 (depends on 43)

The combined measles-malaria vaccine as claimed in claim 43, wherein recombinant measles vaccine virus which expresses at least one malaria antigens selected from d83-30-38 and d42 and d190 fragments of MSP1 or Diversity Covering (DiCo) AMA11 or CS protein.

### Claim 56 (depends on 43)

The combined measles-malaria vaccine as claimed in claim 43, wherein recombinant measles vaccine virus which expresses two or more malaria antigens selected from d83-30-38 and d42 and d190 fragments of MSP1 or Diversity Covering (DiCo) AMA1 or CS protein or combination thereof.

### Claim 57 (depends on 43)

The combined measles-malaria vaccine as claimed in claim 43, wherein recombinant measles vaccine virus comprises the following sequences: TABLE-US-00001 MSP-1 d-190-3D7 AN101TE MSP-1 d-190*-3D7 AN102TE MSP-1 d-83-30-38-3D7 AN103TE MSP-1 d-83-30-38*-3D7 AN104TE MSP-1 d-42-3D7 AN105TE MSP-1 d-42*-3D7 AN106TE MSP-1 d-190-FCB1 AN107TE CS AN108TE DiCo1-complete AN109TE DiCo1-ecto and AN110TE.

### Claim 58 (depends on 43)

The combined measles-malaria vaccine as claimed in claim 43, wherein recombinant measles vaccine virus furthering encoding a protein with adjuvantic properties.

### Claim 59 (depends on 43)

The vaccine as claimed in claim 43, further comprising an interleukin, preferably interleukin 2.

### Claim 60 (depends on 43)

The vaccine as claimed in claim 43, comprises one of the described recombinant measles malaria viruses or a mixture of two to several such viruses.

### Claim 61 (depends on 43)

The vaccine as claimed in claim 43, being a component of a combined vaccine where the other components are rubella, mumps, varicella or another life attenuated vaccine virus, naturally attenuated or recombinant, alone or in combination.

### Claim 62 (depends on 43)

The vaccine as claimed in claim 43, for parenteral administration comprising a suitable stabilizer, such as gelatin and/or human serum albumin and sorbitol.

### Claim 63 (depends on 43)

The vaccine as claimed in claim 43, comprising a suitable stabilizer and/or adjuvant wherein the stabilizer and/or adjuvant are such that the vaccine can be administered parenterally, intranasally, by inhalation, orally, transdermally or in a suppository.

### Claim 64 (depends on 43)

A composition comprising the combined measles-malaria vaccine as claimed in claim 43, comprising stabilizer and/or adjuvant.
